These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

842 related articles for article (PubMed ID: 15308713)

  • 21. Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag.
    Zhao J; Voltan R; Peng B; Davis-Warren A; Kalyanaraman VS; Alvord WG; Aldrich K; Bernasconi D; Buttò S; Cafaro A; Ensoli B; Robert-Guroff M
    Virology; 2005 Nov; 342(1):1-12. PubMed ID: 16109434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B.
    Yu S; Feng X; Shu T; Matano T; Hasegawa M; Wang X; Ma H; Li H; Li Z; Zeng Y
    Vaccine; 2008 Nov; 26(48):6124-31. PubMed ID: 18812199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo induction of cellular and humoral immune responses by hybrid DNA vectors encoding simian/human immunodeficiency virus/hepatitis B surface antigen virus particles in BALB/c and HLA-A2-transgenic mice.
    Marsac D; Puaux AL; Rivière Y; Michel ML
    Immunobiology; 2005; 210(5):305-19. PubMed ID: 16164038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunization with HIV-1 subtype B gp160-DNA induces specific as well as cross reactive immune responses in mice.
    Arora A; Seth P
    Indian J Med Res; 2001 Jul; 114():1-9. PubMed ID: 11762199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines.
    Megede JZ; Otten GR; Doe B; Liu H; Srivastava R; Greer C; Legg H; Tang T; Polo JM; Donnelly JJ; Ulmer JB; Barnett SW
    Vaccine; 2006 Apr; 24(15):2755-63. PubMed ID: 16460840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes.
    Hinkula J; Svanholm C; Schwartz S; Lundholm P; Brytting M; Engström G; Benthin R; Glaser H; Sutter G; Kohleisen B; Erfle V; Okuda K; Wigzell H; Wahren B
    J Virol; 1997 Jul; 71(7):5528-39. PubMed ID: 9188627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model.
    Rollman E; Mathy N; Bråve A; Boberg A; Kjerrström A; van Wely C; Engström G; Johansson S; Aperia K; Eriksson LE; Benthin R; Ertl P; Heeney J; Hinkula J; Voss G; Wahren B
    Vaccine; 2007 Mar; 25(11):2145-54. PubMed ID: 17254672
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice.
    Shinoda K; Xin KQ; Jounai N; Kojima Y; Tamura Y; Okada E; Kawamoto S; Okuda K; Klinman D; Okuda K
    Vaccine; 2004 Sep; 22(27-28):3676-90. PubMed ID: 15315847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
    Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
    J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
    Gómez CE; Abaitua F; Rodríguez D; Esteban M
    Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine.
    Wang S; Farfan-Arribas DJ; Shen S; Chou TH; Hirsch A; He F; Lu S
    Vaccine; 2006 May; 24(21):4531-40. PubMed ID: 16140431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferon regulatory factor-1 acts as a powerful adjuvant in tat DNA based vaccination.
    Castaldello A; Sgarbanti M; Marsili G; Brocca-Cofano E; Remoli AL; Caputo A; Battistini A
    J Cell Physiol; 2010 Sep; 224(3):702-9. PubMed ID: 20432465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans.
    Buttò S; Fiorelli V; Tripiciano A; Ruiz-Alvarez MJ; Scoglio A; Ensoli F; Ciccozzi M; Collacchi B; Sabbatucci M; Cafaro A; Guzmán CA; Borsetti A; Caputo A; Vardas E; Colvin M; Lukwiya M; Rezza G; Ensoli B;
    J Infect Dis; 2003 Oct; 188(8):1171-80. PubMed ID: 14551888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reconstruction and function of ancestral center-of-tree human immunodeficiency virus type 1 proteins.
    Rolland M; Jensen MA; Nickle DC; Yan J; Learn GH; Heath L; Weiner D; Mullins JI
    J Virol; 2007 Aug; 81(16):8507-14. PubMed ID: 17537854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Immunogenicities and comparison of DNA vaccines encoding pol genes derived from B`/C and A/E recombinant HIV-1 strains].
    Wan YM; Ren YQ; Wang J; Ren XN; Hu ZD; Qiu C; Xu JQ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2012 Jun; 46(6):551-5. PubMed ID: 22943905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel codon-optimized GM-CSF gene as an adjuvant to enhance the immunity of a DNA vaccine against HIV-1 Gag.
    Qiu JT; Chang TC; Lin CT; Chen YM; Li FQ; Soong YK; Lai CH
    Vaccine; 2007 Jan; 25(2):253-63. PubMed ID: 16971027
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potent cross-reactive immune response against the wild-type and drug-resistant forms of HIV reverse transcriptase after the chimeric gene immunization.
    Starodubova E; Boberg A; Ivanov A; Latyshev O; Petrakova N; Kuzmenko Y; Litvina M; Chernousov A; Kochetkov S; Karpov V; Wahren B; Isaguliants MG
    Vaccine; 2010 Feb; 28(8):1975-86. PubMed ID: 20188253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine.
    Cristillo AD; Wang S; Caskey MS; Unangst T; Hocker L; He L; Hudacik L; Whitney S; Keen T; Chou TH; Shen S; Joshi S; Kalyanaraman VS; Nair B; Markham P; Lu S; Pal R
    Virology; 2006 Mar; 346(1):151-68. PubMed ID: 16325880
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Peptide mapping of H-2d restricted T-cell epitope against six antigens of HIV-1 subtype B'/C by ELISPOT assay].
    Qi XR; Gao YY; Lu RJ; Deng Y; Meng X; Tan WJ; Ruan L
    Bing Du Xue Bao; 2011 Jan; 27(1):34-43. PubMed ID: 21462504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.